The Effect of Novel Antihyperglycemic Treatments on Sarcopenia in Type 2 Diabetic Patients

Büşra Can; Zehra Kaya; Bülent Can

Makale detayları

The Effect of Novel Antihyperglycemic Treatments on Sarcopenia in Type 2 Diabetic Patients

Yazarlar:

Büşra Can | Zehra Kaya | Bülent Can

Yayıncı:

Zonguldak Bulent Ecevit University

Ana Başlıklar:

Endokrinoloji

Dergi:

Türkiye Diyabet ve Obezite Dergisi Vol.9 Issue 2, pp.97-106

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357608

pISSN:

2587-0335

Anahtar kelimeler:

Özet:

 Aim: Previous studies indicate a possible association between weight losing interventions and reduced muscle function. There is scarce research on how novel glucose-lowering agents effect sarcopenia parameters. The present study aims to investigate the longitudinal relationship between current antihyperglycemic treatments and sarcopenia. Material and Methods: Type 2 diabetic patients aged 18 and above were enrolled in this longitudinal observational study. Patient characteristics, list of medications, hours of physical activity per week, laboratory values, anthropometric measurements, handgrip strength and body composition analyzed with bioelectrical impedance analysis were recorded at the initial presentation and at 6 months. Results: A total of 109 women 76 and 34 men 24 with type 2 diabetes mellitus DM were included. The mean age of study participants was 53.410.4 years, and the mean duration of DM was 10.28 years. At 6 months, weight, total fat mass, visceral fat mass, waist circumference, HbA1c, fasting glucose, serum insulin, LDL low density lipoprotein and vitamin B12 levels were significantly lower while muscle strength was significantly higher p0.012. There was a significant inverse association between age and muscle strength both initially and at 6 months p0.001 and 0.001 for women; p0.005 and 0.001 for men, respectively. Duration of DM was inversely associated with muscle strength only for women p0.02 at initial presentation and p0.001 at month 6. Frequency of probable sarcopenia was reduced at month 6 for both genders p0.029 for women and 0.5 for men. Conclusion: Glycemic control has a favorable effect on muscle function despite weight loss. Effective management of DM with novel antihyperglycemic agents may help prevent sarcopenia.

 Aim: Previous studies indicate a possible association between weight losing interventions and reduced muscle function. There is scarce research on how novel glucose-lowering agents effect sarcopenia parameters. The present study aims to investigate the longitudinal relationship between current antihyperglycemic treatments and sarcopenia. Material and Methods: Type 2 diabetic patients aged 18 and above were enrolled in this longitudinal observational study. Patient characteristics, list of medications, hours of physical activity per week, laboratory values, anthropometric measurements, handgrip strength and body composition analyzed with bioelectrical impedance analysis were recorded at the initial presentation and at 6 months. Results: A total of 109 women 76 and 34 men 24 with type 2 diabetes mellitus DM were included. The mean age of study participants was 53.410.4 years, and the mean duration of DM was 10.28 years. At 6 months, weight, total fat mass, visceral fat mass, waist circumference, HbA1c, fasting glucose, serum insulin, LDL low density lipoprotein and vitamin B12 levels were significantly lower while muscle strength was significantly higher p0.012. There was a significant inverse association between age and muscle strength both initially and at 6 months p0.001 and 0.001 for women; p0.005 and 0.001 for men, respectively. Duration of DM was inversely associated with muscle strength only for women p0.02 at initial presentation and p0.001 at month 6. Frequency of probable sarcopenia was reduced at month 6 for both genders p0.029 for women and 0.5 for men. Conclusion: Glycemic control has a favorable effect on muscle function despite weight loss. Effective management of DM with novel antihyperglycemic agents may help prevent sarcopenia.

 Aim: Previous studies indicate a possible association between weight losing interventions and reduced muscle function. There is scarce research on how novel glucose-lowering agents effect sarcopenia parameters. The present study aims to investigate the longitudinal relationship between current antihyperglycemic treatments and sarcopenia. Material and Methods: Type 2 diabetic patients aged 18 and above were enrolled in this longitudinal observational study. Patient characteristics, list of medications, hours of physical activity per week, laboratory values, anthropometric measurements, handgrip strength and body composition analyzed with bioelectrical impedance analysis were recorded at the initial presentation and at 6 months. Results: A total of 109 women 76 and 34 men 24 with type 2 diabetes mellitus DM were included. The mean age of study participants was 53.410.4 years, and the mean duration of DM was 10.28 years. At 6 months, weight, total fat mass, visceral fat mass, waist circumference, HbA1c, fasting glucose, serum insulin, LDL low density lipoprotein and vitamin B12 levels were significantly lower while muscle strength was significantly higher p0.012. There was a significant inverse association between age and muscle strength both initially and at 6 months p0.001 and 0.001 for women; p0.005 and 0.001 for men, respectively. Duration of DM was inversely associated with muscle strength only for women p0.02 at initial presentation and p0.001 at month 6. Frequency of probable sarcopenia was reduced at month 6 for both genders p0.029 for women and 0.5 for men. Conclusion: Glycemic control has a favorable effect on muscle function despite weight loss. Effective management of DM with novel antihyperglycemic agents may help prevent sarcopenia.

 Amaç: Sarkopeni parametrelerinin glisemik kontrol ile ilişkisini inceleyen çok az sayıda araştırma bulunmaktadır. Bu çalışma, yeni diyabet tedavileri ile sarkopeni arasındaki uzunlamasına ilişkiyi araştırmayı amaçlamaktadır. Gereç ve Yöntemler: Tip 2 diyabetik 18 yaş ve üzeri hastalar bu çalışmaya dahil edildi. Hastaların demografik özellikleri, kullandıkları ilaçlar, haftalık fiziksel aktivite saati, laboratuvar değerleri, antropometrik ölçümleri, el kavrama kuvveti ve biyoelektrik empedans analizi ile analiz edilen vücut kompozisyonu başvuruda ve altıncı ayda kaydedildi. Bulgular: Tip 2 diabetes mellitus tanılı toplam 109 kadın 76 ve 34 erkek 24 dahil edildi. Çalışmaya katılanların ortalama yaşı 53,410,4 yıl ve ortalama diyabet süresi 10,28 yıldı. 6. ayda, kilo, toplam yağ kütlesi, viseral yağ kütlesi, bel çevresi, HbA1c, açlık glikozu, serum insülin, LDL düşük yoğunluklu lipoprotein ve B12 vitamini düzeyleri azalırken kas gücü anlamlı düzeyde arttı p0,012. Yaş ve kas gücü arasında hem başlangıçta hem de 6. ayda önemli bir ters ilişki vardı kadınlar için p0,001 ve 0,001; erkekler için sırasıyla p0,005 ve 0,001. Diyabet süresi yalnızca kadınlarda kas gücüyle ters ilişkiliydi ilk başvuruda p0,02 ve 6. ayda p0,001. Olası sarkopeni sıklığı her iki cinsiyet için de 6. ayda azaldı kadınlar için p0,029 ve erkekler için 0,5. Sonuç: Glisemik kontrolün kas fonksiyonu üzerinde olumlu bir etkisi vardır. Kilo verdirici özelliği olan yeni antidiyabetik tedaviler sarkopeniyi önlemektedir.

Makale detayları

The Effect of Novel Antihyperglycemic Treatments on Sarcopenia in Type 2 Diabetic Patients

Yazarlar:

Büşra Can | Zehra Kaya | Bülent Can

Yayıncı:

Zonguldak Bulent Ecevit University

Ana Başlıklar:

Endokrinoloji

Dergi:

Türkiye Diyabet ve Obezite Dergisi Vol.9 Issue 2, pp.97-106

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357608

pISSN:

2587-0335

Antidiabetics

Diabetes mellitus

GLP-1 Receptor agonists

Muscle strength

Sarcopenia

SGLT-2 inhibitorsAntidiyabetikler

Diabetes mellitus

GLP-1 Reseptör agonistleri

Kas kuvveti

Sarkopeni

SGLT-2 inhibitörleri

Sayı

Makale detayları

Yazarlar: Büşra Can | Zehra Kaya | Bülent Can

Yayıncı: Zonguldak Bulent Ecevit University

Ana Başlıklar: Endokrinoloji

Dergi: Türkiye Diyabet ve Obezite Dergisi Vol.9 Issue 2, pp.97-106

Belge Tipi: Makale

Yayın Tarihi: 8/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001357608

pISSN: 2587-0335

Sayı

Yazarlar:

Büşra Can | Zehra Kaya | Bülent Can

Yayıncı:

Zonguldak Bulent Ecevit University

Ana Başlıklar:

Endokrinoloji

Dergi:

Türkiye Diyabet ve Obezite Dergisi Vol.9 Issue 2, pp.97-106

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357608

pISSN:

2587-0335